Rejuran I

Rejuran I 1 ml – Polynucleotide Injectable for the Periorbital Area Rejuran I is the periorbital formulation of PharmaResearch’s Rejuran range, developed for the thin, mobile skin of the eye area. The lower-concentration salmon-derived PN gel is used where the presenting problem is crepey texture, translucency and loss of dermal quality rather than volume. Supplied as a 1 ml pre-filled syringe, its reduced viscosity allows controlled low-volume intradermal placement in eyelid skin, where standard-viscosity product is more difficult to deposit and papules remain visible longer. Key features ✓ CE-marked injectable medical device ✓ 1% salmon-derived polynucleotide ✓ Salmon-derived, no human-origin components ✓ 1 ml pre-filled syringe ✓ Formulated for thin periorbital skin ✓ No hyaluronic acid, no volumising effect Product overview Feature Value Category Polynucleotide regenerative injectable Active substance Sodium polynucleotide (PN), 1% DNA source Salmon Mechanism Dermal regeneration, matrix remodelling Injection depth Superficial dermis Technique Microdroplet, per IFU Primary area Lower eyelid, tear trough region, lateral canthal lines Secondary areas Perioral area, forehead, thin décolleté skin Patient profile Thin, crepey or fatigued periorbital skin Volume per session Approximately 0.5 ml per side Sessions 3-4, approximately 2-4 weeks apart Final assessment 4-8 weeks after last session Maintenance Every 6-12 months Downtime Minimal Mechanism Polynucleotides are high-molecular-weight deoxyribonucleotide polymers. As a product class they are described in the clinical literature as supporting fibroblast activity and extracellular matrix remodelling, with the injected gel forming a temporary dermal scaffold that is progressively resorbed. In the periorbital area the objective is improved dermal thickness and elasticity in tissue that has little of either. The gel resorbs. The remodelled dermis remains. Rejuran I does not fill. Improvement in texture, crepiness, fine lines and the translucency that contributes to visible dark circles develops across the course, with outcome assessed four to eight weeks after the final session. Treatment areas Primary: lower eyelid, tear trough region, lateral canthal lines, upper eyelid skin where laxity is dermal rather than structural. Secondary: perioral fine lines, forehead, and other areas where the dermis is too thin for standard-viscosity product. A large share of patients requesting eye-area treatment describe pigment and shadow rather than volume. Separating the dermal, pigmentary, vascular and structural components at consultation determines whether polynucleotide treatment is the correct selection; hollowing from orbital fat compartment loss or a bony tear trough deficit requires a dermal filler . Within the same class, Croma PolyPhil Eye is the trout-derived equivalent for this region, and Nucleofill Soft Plus the low-concentration salmon-derived option. Where an amino acid and HA formulation is preferred, Jalupro Young Eye addresses the same area through a different mechanism. Rejuran range Feature Rejuran I Rejuran Rejuvenation with PN Rejuran HB Plus Composition PN only PN only PN + HA + lidocaine PN concentration 1% 2% 2% Volume 1 ml 2 ml 1 ml Primary area Periorbital Full face, neck, décolleté Face, neck, décolleté Objective Thin-skin regeneration Dermal regeneration Regeneration with hydration Anaesthetic in product No No Yes Administration Depth: superficial dermis. Injection depth is an important factor in the visibility and persistence of post-injection papules. Technique: microdroplet, with point spacing and volume per point according to IFU and injector preference; approximately 0.5 ml per side per session. Needle or cannula: selected by area and technique; see the available cannulas and needles . Observe the vascular anatomy of the region, particularly the angular vessels at the medial canthus. Anaesthesia: the product contains none; topical anaesthesia is applied at the practitioner’s discretion. Safety profile Common reactions are injection papules, periorbital oedema, erythema and bruising, typically resolving within one to three days; oedema may persist slightly longer than at other sites. Less commonly reported: prolonged papule visibility following excessively superficial placement in very thin skin, injection-site infection, post-inflammatory hyperpigmentation and hypersensitivity to fish-derived material. Contraindications The following are general considerations and do not replace the product-specific Instructions for Use. Known hypersensitivity to any component of the product; review any history of hypersensitivity to fish-derived materials Active periorbital infection, blepharitis, inflammation or skin lesions Pregnancy and breastfeeding Patients under 18 years of age Recent ophthalmic surgery requires individual medical assessment before periorbital treatment Specification Active substance Sodium polynucleotide (PN), 1% Volume 1 ml per pre-filled syringe Pack 1 syringe + package insert Anaesthetic None Storage As specified in the manufacturer’s IFU. Protect from light. Do not freeze. Shelf life 17 months, unopened Manufacturer PharmaResearch Co., Ltd. Classification CE-marked injectable medical device, MFDS registered Availability Licensed medical professionals only FAQ Why a lower concentration than the standard format? The periorbital dermis is thin and mobile. The lower-viscosity formulation allows precise low-volume intradermal placement in eyelid skin and shortens the time injection papules remain visible. Does it treat dark circles? Partially. It addresses dermal thickness and skin translucency, so shadowing driven by thin skin responds. Pigmentary and structural components require a different or combined approach. Can it replace filler in the tear trough? No. True volume deficit requires structural correction. Rejuran I applies where the problem is skin quality, crepiness or translucency, and it can precede filler in staged protocols. How much product per session? Approximately 0.5 ml per side, so one syringe covers a standard bilateral periorbital session. The usual protocol is three to four sessions spaced two to four weeks apart. When is the 2 ml format the better choice? When the treatment field extends beyond the eye area. The 2 ml formulation is intended for full face, neck and décolleté, where 1 ml would not cover the surface treated.